#biotech

🏢Release 📈 Stocks

BRC Therapeutics Appoints Kimberly Spancake as Senior Director of Clinical

November 5, 2026 (5 days ago)

BRC Therapeutics strengthens its clinical leadership team with the appointment of Kimberly Spancake, a veteran drug development executive with over two decades…

BRC

🌍 US Read More →

📊Earnings 📈 Stocks

ChemoMetec Q1 Revenue Climbs 28% to DKK 160M on Strong Instrument Sales

November 5, 2026 (5 days ago)

ChemoMetec posted a 28% revenue increase and 46% EBITDA growth in Q1 2026/27, fueled by a 61% surge in instrument sales and…

CHEMM.CO

🌍 DK Read More →

🏛️Filing 📈 Stocks

Xeris Biopharma Holdings Files Q3 Results of Operations in 8-K Disclosure

November 5, 2026 (5 days ago)

Xeris Biopharma Holdings has officially filed its latest financial results with the SEC, providing investors with updated operational data and supporting exhibits…

XERS

🌍 US Read More →

📊Earnings 📈 Stocks

REGENXBIO Targets Q1 2027 for RGX-202 BLA Submission Amid Pipeline Progress

November 5, 2026 (5 days ago)

REGENXBIO maintains its clinical roadmap, targeting a 2027 BLA filing for its Duchenne muscular dystrophy candidate and preparing for key wet AMD…

RGNX

🌍 US Read More →

🏢Release 📈 Stocks

Eli Lilly Reports Positive Phase 3 Retatrutide Data for Knee Osteoarthritis

November 5, 2026 (5 days ago)

Eli Lilly shares see potential upside as Phase 3 trials for retatrutide show substantial efficacy in treating knee osteoarthritis and obesity, with…

LLY

🌍 US Read More →

📰News 📈 Stocks

Akeso Receives NMPA Priority Review for Ivonescimab in Biliary Tract Cancer

November 5, 2026 (5 days ago)

Akeso's ivonescimab secures NMPA Priority Review status for first-line biliary tract cancer treatment, marking a potential regulatory milestone for the company's lead…

9926.HK

🌍 CN Read More →

🏢Release 📈 Stocks

Belay Diagnostics Secures Second Consecutive Palantir Buildcamp Victory

November 4, 2026 (6 days ago)

Belay Diagnostics wins the Palantir Buildcamp for the second year running, highlighting its advancements in molecular diagnostics and automated insurance appeals technology.

PLTR

🌍 US Read More →

🏢Release 📈 Stocks

TuHURA Biosciences to Present 3 Studies at 68th ASH Annual Meeting

November 4, 2026 (6 days ago)

TuHURA Biosciences prepares to present new research on the Delta Opioid Receptor's role in immune regulation at the upcoming 68th American Society…

HURA

🌍 US Read More →

🏢Release 📈 Stocks

Genprex Identifies TROP2 Biomarker to Predict REQORSA Response in Lung Cancer

November 4, 2026 (6 days ago)

Genprex research links TROP2 expression to REQORSA efficacy, suggesting that low levels of the protein may serve as a marker for primary…

GNPX

🌍 US Read More →

🏢Release 📈 Stocks

UCB Selects Veeva Vault CRM to Standardize Global Engagement Platform

November 4, 2026 (6 days ago)

UCB selects Veeva Vault CRM to streamline global operations, reinforcing Veeva Systems' position as a key technology partner in the biopharmaceutical industry.

VEEV

🌍 US Read More →

🏢Release 📈 Stocks

Viking Therapeutics Schedules Participation at Stifel 2026 Investor Conference

November 3, 2026 (6 days ago)

Viking Therapeutics confirms participation in the Stifel 2026 investor conference to discuss its clinical-stage metabolic and endocrine therapy development programs.

VKTX

🌍 US Read More →

🏢Release 📈 Stocks

Neurocrine Biosciences to Showcase Neuropsychiatry Pipeline at 2026 NEI Congress

November 3, 2026 (6 days ago)

Neurocrine Biosciences is set to detail its neuropsychiatry pipeline and scientific advancements during the 2026 NEI Fall Congress, running from November 5…

NBIX

🌍 US Read More →